Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-05-29

Neumora Therapeutics (NMRA)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$4,562,461
Paul Berns total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
99.68%
Say-on-pay support, latest vote
Companies that benchmark against NMRA
4 companies name NMRA as a compensation peer

Each company listed discloses NMRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NMRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Paul Berns$700,000$21,000$0$3,326,181$504,000$0$11,280$4,562,461
Chief Executive Officer
Henry Gosebruch94,231420,000086,26300718,7791,319,273
Former President and Chief Executive Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Paul Berns$4,562,461$8,648,393−4,085,932
Henry Gosebruch1,319,2734,785,930−3,466,657

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
David PiacquadDirector2026-05-27A80,000$0$0Derivative, Class A CommonForm 4 ↗
Alaa HalawaDirector2026-05-27A80,00000Derivative, Class A CommonForm 4 ↗
Maykin HoDirector2026-05-27A80,00000Derivative, Class A CommonForm 4 ↗
Matthew FustDirector2026-05-27A80,00000Derivative, Class A CommonForm 4 ↗
Kristina BurowDirector2026-05-27A80,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Henry GosebruchOption$86,263
Paul BernsOption3,326,181
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Henry Gosebruch$0$0$86,2630.0%
Paul Berns003,326,1810.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
AuroraOption100,3670.72
AuroraOption105,6260.72
PintoOption47,7930.72
AuroraOption1,000,0000.72
AuroraOption38,2360.72
PintoOption92,0840.72
PintoRSU63,750114,113
PintoOption3,000,0000.72
PintoOption30,0040.72
PintoOption37,1740.72
AuroraRSU4,7808,556
Paul BernsOption20,7110.72
Paul BernsOption2,000,0000.72
Paul BernsOption378,3630.72
Paul BernsRSU128,438229,904
Paul BernsOption185,5210.72
AuroraRSU73,125130,894
05

Incentive-plan design — the Compensation Discussion & Analysis

Our Compensation Committee and Board believe that the information provided in the section of this proxy statement titled "Executive Compensation", the compensation tables and accompanying narrative disclosure demonstrates that our executive compensation program is designed appropriately, emphasizes pay for performance and aligns management's interests with our stockholders' interests to support long-term value creation.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAlpine Rewards, LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-27131,998,871420,917274,53599.68%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2799.68%a

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Matthew FustIndependent · Audit (Chair) · Compensation$90,625$0$43,632$0$134,257
Kristina BurowIndependent · Compensation (Chair) · Nominating/Governance67,500043,6320111,132
Alaa HalawaIndependent · Nominating/Governance (Chair) · Compensation62,500043,6320106,132
Maykin Ho, Ph.DIndependent · Audit · Nominating/Governance60,000043,6320103,632
David PiacquadIndependent · Audit53,750043,632097,382
Paul L. BernsEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$43,632
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$334,375
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$334,375

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Neumora Therapeutics2025Paul Berns$700,000$0$3,326,181$504,000$4,562,461

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Paul BernsDEF 14A2026-04-170001193125-26-161489Section “2025 Summary Compensation Table”. As printed: 4,562,461. Filing ↗machine: r2 · c29 · span 444810–444819
2Section 01, Henry GosebruchDEF 14A2026-04-170001193125-26-161489Section “2025 Summary Compensation Table”. As printed: 1,319,273. Filing ↗machine: r8 · c29 · span 510036–510045
3Section 03, Henry Gosebruch OptionDEF 14A2026-04-170001193125-26-161489Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t7 · r8 · c17 · span 505909–505915
4Section 03, Paul Berns OptionDEF 14A2026-04-170001193125-26-161489Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t7 · r2 · c17 · span 440681–440690
5Section 07, pay ratio10-K2026-03-300001193125-26-130388Section “CEO Pay Ratio”. As printed: —. Filing ↗
6Section 08, Matthew FustDEF 14A2026-04-170001193125-26-161489Section “Director Compensation”. As printed: 134,257. Filing ↗machine: t5 · r3 · c11 · span 366985–366992
7Section 08, Kristina BurowDEF 14A2026-04-170001193125-26-161489Section “Director Compensation”. As printed: 111,132. Filing ↗machine: t5 · r2 · c11 · span 362391–362398
8Section 08, Alaa HalawaDEF 14A2026-04-170001193125-26-161489Section “Director Compensation”. As printed: 106,132. Filing ↗machine: t5 · r4 · c11 · span 371578–371585
9Section 08, Maykin Ho, Ph.DDEF 14A2026-04-170001193125-26-161489Section “Director Compensation”. As printed: 103,632. Filing ↗machine: t5 · r5 · c11 · span 376176–376183
10Section 08, David PiacquadDEF 14A2026-04-170001193125-26-161489Section “Director Compensation”. As printed: 97,382. Filing ↗machine: t5 · r6 · c11 · span 380772–380778
11Section 08, Paul L. BernsDEF 14A2026-04-170001193125-26-161489Section “Director Compensation”. As printed: 0. Filing ↗
12Section 02, David Piacquad 2026-05-27Form 42026-05-290001610717-26-000171Insider equity transaction reported since the proxy statement. Filing ↗
13Section 02, Alaa Halawa 2026-05-27Form 42026-05-290001610717-26-000170Insider equity transaction reported since the proxy statement. Filing ↗
14Section 02, Maykin Ho 2026-05-27Form 42026-05-290001610717-26-000169Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Matthew Fust 2026-05-27Form 42026-05-290001610717-26-000173Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Kristina Burow 2026-05-27Form 42026-05-290001610717-26-000174Insider equity transaction reported since the proxy statement. Filing ↗
17Section 06, 2026 voteForm 8-K2026-05-290001193125-26-248244Item 5.07 · say-on-pay result. As reported: 99.68% (votes for as printed: 131,998,871). Filing ↗
18Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
19Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
20Section 09b board cost (computed)ComputedcomputedCash 334,375 + equity 0 + all other 0 = 334,375, summed across the director compensation table rows.machine: formula: Σ = 334,375
21Neumora Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-170001193125-26-161489CEO total compensation as printed in Neumora Therapeutics's own proxy. As printed: 4,562,461. Filing ↗machine: r2 · c29 · span 444810–444819